

## Colorado COVID-19 Vaccine Screening and Administration Form



	Administration Louis						
	orint neatly in capital letters as shown in the example: Please answer all questions as completely as possible.  X A M P L E 1 2 3 Please use only black ink to complete form.  The administration record of this document.	d is on the I	everse	side			
Please	Please complete ALL the information below as accurately as possible. If you are completing this form for your minor						
child,	do not use nick-names or abbreviations, except where allowed. All information will be kept conf	idential.					
.ast Na	me First Name		^	<u>\.l.</u>			
				_] [			
Date o	Age (years)  Patient/Representative Daytime Pho	ne Numbe	er				
M	M D D Y Y Y Y  18 years Parent First Name  Parent Last Name	· · · · · · · · · · · · · · · · · · ·					
of age p	please		-				
Addre	Ant N	umber					
LL City	County	State					
Zip Co	ode E-mail Address			$\neg 1$			
			<u></u>				
Gende	r Identity F M Transgender Female/Feminine Transgender Male/Masculine Non-Binary Un-specified	Decline	to Prov	nde			
•	bu Hispanic/Latin/a/o/x? Race(s) check all that apply  American Indian/Alaskan Native Native Hawaiian/Pacific Islander Decline	to Provide					
_	□ NO □ Asian □ Other						
	line to Provide Black, African American White  Insurance (OPTIONAL-INSURANCE NOT REQUIRED FOR VACCINATION) Insurance Policy Number						
	edicaid Medicare Kaiser Permanente Other Private No Insurance						
If you h	ave already been vaccinated with a COVID-19 vaccine, please tell us which vaccine(s) was received, the number of doses, and the date(s) of va	ccination.					
Dose(s)	received: Dose 1: Vaccine Brand Vaccination Date/  Dose 2: Vaccine Brand Vaccination Date			Don't			
Healt	h Screening Questions	Yes	No	Know			
1.	Are you or your child sick today or have a fever?						
. 2.	Have you or your child had an allergic reaction to polysorbate, polyethylene glycol, or a previous dose of COVID-19 vaccine?						
3.	Have you or your child ever had a serious allergic reaction (anaphylaxis) to another vaccine or any injectable medication?		W. E. V.				
4.	Have you or your child had severe allergic reaction (anaphylaxis) to foods, pets, venom, environmental or oral medications?	Brani kulinda	ga kinis	New N			
5.	Do you or your child have a bleeding disorder, are on long-term aspirin therapy, or take other blood thinners?	,	5:023				
6.	Have you or your child ever had Guillain-Barré Syndrome (a type of temporary severe muscle weakness) after receiving a vaccine		i veni				
7.	Have you or your child had convalescent plasma or monoclonal antibodies as part of COVID-19 treatment in the past 3 months?		A COLOR				
8.	Have you received any dermal fillers (Juvaderm®, Restylane®, etc.)? (only applies to mRNA vaccines)	set l					
9.	Do you have a history of blood clots or have risk factors for developing blood clots? (Janssen vaccine only, applies to females at 18-49)						
10.	Do you or your child have a history of myocarditis or pericarditis? (Especially males ages 12-29 years after receiving a dose of mRNA vaccine)		13.3	i de ciento			
11.	Do you or your child have a history of heparin-induced thrombocytopenia (HIT)?						
12.	Do you or your child have a history of Multisystem Inflammatory Syndrome known as MIS-C (in children) or MIS-A (in adults) after a COVID-19 infection?						
13.	Are you or your child immunocompromised? (See additional dose section on next page)						
14.	Do you have an underlying medical condition that puts you at high risk for severe COVID-19? (Applies to adults 18-64) (See booste dose section)						
15.	Are you at increased risk for COVID-19 because of where you work or live? (Applies to adults age 18-64) (See booster dose section	n)   Continue	d on Ne	yt Page			
09/20/20	a de la companya de						

Last Name First Name								
Last Name								
Date of Birth M M M	Dose Number	r: 1 2 3						
Authorization to Administer COVID-19 Vaccine  I have read or had explained to me the Emergency Use Authorization for the use of the COVID-19 vaccine and understand the benefits and risks to me or my large read or had explained to me the Emergency Use Authorization which were appropried to my satisfaction. Thereby release this provider, its employees								
I have read or had explained to me the Emergency Use Authorization for the use of the COVID-19 vaccine and discovering this vaccine. I have had a chance to ask questions, which were answered to my satisfaction. I hereby release this provider, its employees child of receiving this vaccine. I have had a chance to ask questions, which were answered to my satisfaction. I hereby release this provider, its employees and its volunteers from any liability for any results which may occur from the administration of this vaccine.								
Signature of Patient/Parent/Legal Guardian/ Medical Durable Power of Attorney:								
Medical Durable Power of Attorn								
Medical Durable Power of Attorn	STOP: DO NOT WRITE BELOW THIS LINE-F							
Medical Durable Power of Attorn	STOP: DO NOT WRITE BELOW THIS LINE-F							
Medical Durable Power of Attorn  COVID/VFC PIN	STOP: DO NOT WRITE BELOW THIS LINE-F	OR CLINIC STAFF ONLY  Provider Name						
Medical Durable Power of Attorn  COVID/VFC PIN	STOP: DO NOT WRITE BELOW THIS LINE-F rovider Type   Clinic Name	OR CLINIC STAFF ONLY  Provider Name						
Medical Durable Power of Attorn  COVID/VFC PIN	STOP: DO NOT WRITE BELOW THIS LINE-F rovider Type Private  Clinic Name Private	Provider Name  Provider Name  Date Administered  LD LT / / / / / / / / / / / / / / / / / /						
Medical Durable Power of Attorn  COVID/VFC PIN  Manufacturer  PFR (Pfizer) AstraZeneca	STOP: DO NOT WRITE BELOW THIS LINE-F rovider Type Public Private Lot Number Dosag	Provider Name    Provider Name						
Medical Durable Power of Attorn  COVID/VFC PIN  Manufacturer  PFR (Pfizer) AstraZeneca  Moderna Novavax	STOP: DO NOT WRITE BELOW THIS LINE-F rovider Type Public Private Lot Number Dosag	Provider Name  Provider Name  Date Administered  LD LT / / / / / / / / / / / / / / / / / /						

## ADDITIONAL DOSE INFORMATION

- Currently, CDC is recommending that moderately to severely immunocompromised people receive an additional dose. Applies to: Pfizer vaccine - age 12 and over; Moderna vaccine - ages 18 and over at this time. Effective 8/13/2021 for those who have:
  - Been receiving active cancer treatment for tumors or cancers of the blood
  - Received an organ transplant and are taking medicine to suppress the immune system
  - Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
  - Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
  - Advanced or untreated HIV infection
  - Active treatment with high-dose corticosteroids or other drugs that may suppress immune response ((i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory).
  - The additional mRNA COVID-19 vaccine dose should be the same vaccine product as the initial 2-dose mRNA COVID-19 primary vaccine series (Pfizer-BioNTech or Moderna).
- If the mRNA COVID-19 vaccine product given for the first two doses is not available, the other mRNA COVID-19 vaccine product may be administered. A person should not receive more than three mRNA COVID-19 vaccine doses.
- Until additional data are available, the additional dose of an mRNA COVID-19 vaccine should be administered at least 28 days after completion of the initial 2-dose mRNA COVID-19 vaccine series, based on expert opinion.
- Currently there are insufficient data to support the use of an additional mRNA COVID-19 vaccine dose after a single-dose Janssen COVID-19 vaccination series in immunocompromised people. FDA and CDC are actively working to provide guidance on this issue.

## **BOOSTER DOSE INFORMATION**

- Currently, CDC is recommending that the following people receive a booster dose at least 6 months after completion of Pfizer primary series. Applies to Pfizer ONLY. Effective 9/24/21 for:
  - people 65 years and older and residents in long-term care settings should receive a booster shot of Pfizer-BioNTech's COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
  - people aged 50-64 years with underlying medical conditions should receive a booster shot of Pfizer-BioNTech's COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
  - people aged 18-49 years with underlying medical conditions may receive a booster shot of Pfizer-BioNTech's COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks, and
  - people aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting may receive a booster shot of Pfizer-BioNTech's COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks.



## Pfizer-BioNTech COVID-19 Vaccination Consent for Minors

Patient Identification Label				
	E EUO 12 Tags turocado a sabot			
Name	Water Control of the			
MRN				
DOB				
Date of service				

Name (print)	□	Pate of birth
Address		
Phone		
have been given an opportunity to read the <i>Pfizer</i> -read or had explained to me the information about twere answered to my satisfaction. I understand the and its employees from any claims arising out of talwaccine, I understand I am advised to wait 15 min	he COVID-19 vaccine. I have had benefits and risks of the COVID sing this vaccine. Since this is the	d a chance to ask questions which vaccine. I hereby release UCHealth after time I have ever received the
Name of patient (printed)	Relationship to patient	
Signature of parent or legally authorized representative	Date	Time